MEDI 7526
Alternative Names: MEDI-7526Latest Information Update: 28 Jul 2024
At a glance
- Originator AstraZeneca
- Class Antineoplastics; Bispecific antibodies; Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD40 ligand stimulants; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 22 Jun 2020 Preclinical trials in Cancer in USA (Parenteral), before June 2020
- 22 Jun 2020 Pharmacodynamics data from preclinical studies in Cancer presented at the 111th Annual Meeting of the American Association for Cancer Research - II (AACR-2020)